



**MPOG Cardiac Anesthesia Subcommittee Meeting
December 16th, 2024**

Agenda

- Introduction & announcements
- Unblinded Review of measures:
 - ABX-02-C
 - ABX-03-C
 - ABX-04-C
 - ABX-05-C
 - AKI-02-C
- Summary and next steps

Introductions

- **ASPIRE Quality Team**

- **Allison Janda, MD** – MPOG Cardiac Anesthesia Subcommittee Lead
- **Michael Mathis, MD** – MPOG Director of Research
- **Kate Buehler, MS, RN** – Clinical Program Manager

- Cardiac Anesthesiology Representatives joining us from around the US!

Upcoming Cardiac-Focused Measure Reviews

Measure	Review Date	Reviewers
TEMP-06-C: Hypothermia Avoidance	February 2025	Mariya Geube, Cleveland Clinic
TEMP-07-C: Hyperthermia Avoidance	February 2025	Ashan Grewal, UMaryland
GLU-06-C: Hyperglycemia Management	June 2026	Josh Billings, Vanderbilt
GLU-07-C: Hypoglycemia Management	June 2026	Rob Schonberger, Yale
GLU-08-C: Hyperglycemia Treatment	June 2026	Josh Billings, Vanderbilt

Thank you in advance for ensuring MPOG Cardiac-specific measures remain relevant & consistent with published recommendations!

Contact Allison with any questions: ajanda@med.umich.edu

Unblinded Data Review: Antibiotic Compliance Measures

Reminders:

Per the terms and conditions outlined during the registration process:

- A culture of openness and trust are critical to the development of such a collaborative effort to improve quality; and **a commitment for confidentiality is required to further the goals of ASPIRE.**

- The following examples are to be considered privileged and confidential information and should be discussed only within the confines of the Cardiac Subcommittee Meeting.
 - Any and all patient information.
 - Any and all patient identifiers/information which are considered privileged and protected health information as defined by current HIPAA laws.
 - Any specific MPOG QI registry case information.
 - Any information discussed regarding a specific site outcome.
 - Any reference to a specific MPOG site result or analysis.
 - All anesthesiology data presented including but not limited to outcome reports.
 - **Taking screenshots, pictures or videos of data slides is prohibited.**

Site Participation

- All sites that perform >75 open cardiac procedures annually are presented on the slides to follow
- This is a closed meeting: registration required to receive the Zoom link.
- Only those sites who have a participant on the cardiac subcommittee are unblinded
- Cardiac Anesthesia Champions were notified that unblinded data would be shared and were given the opportunity to opt out
- No sites emailed us to express a desire to be excluded from this review

ABX-02 Antibiotic Timing, Open Cardiac

- **Description:**
 - Percentage of adult patients undergoing open cardiac surgery with antibiotic administration initiated within the appropriate time frame before incision (see specification for timing expectations per agent)
- **Timing:**
 - 120 minutes prior to Surgery Start through Surgery Start.
- **Success Criteria:**
 - Documentation of antibiotics administered before surgery start time

ABX-02 Antibiotic Timing Considerations

- **Inclusions:**

- Adult patients undergoing open cardiac surgical procedures (determined by Procedure Type Cardiac: value code 1)


- **Exclusions:**

- Age < 18 years
- ASA 6 including Organ Procurement
- Patients already on scheduled antibiotics or had a documented infection prior to surgery, as determined by ABX Notes Phenotype (value code 2)
- Non-cardiac, Transcatheter/Endovascular, EP/Cath groups and Other Cardiac cases as determined by the Procedure Type: Cardiac phenotype
- Procedure Type: Lung Transplant

Unblinded data removed from slides published to website.

Antibiotic Timing: Breakdown of Flagged Cases

■ Case Count (#)



Unblinded data removed from slides published to website.

ABX-03 Antibiotic Re-dosing, Open Cardiac

- **Description:**

- Percentage of adult patients undergoing open cardiac procedure with an antibiotic re-dose initiated within 3-4 hours after initial antibiotic administration (cephalosporins only).

- **Timing:**

- 120 minutes prior to Anesthesia Start through Surgery End. If Surgery End is not available, then Anesthesia End.

- **Success:**

- Documentation of cephalosporin re-dose within 165-255 minutes after each cephalosporin administration (max: 3 doses)

ABX-03 Antibiotic Re-dosing Considerations

- **Inclusions:**

- Adult patients undergoing open cardiac surgical procedures (determined by Procedure Type Cardiac: value code 1) **and** receiving antibiotic prophylaxis with a cephalosporin

- **Exclusions:**

- Age < 18 years
- ASA 6 including Organ Procurement
- Cases where Surgery End time is before re-dose (less than 4 hours and 15 minutes after cephalosporin dose)
- Cases without administration of a cephalosporin for antibiotic prophylaxis
- Patients already on scheduled antibiotics or had a documented infection prior to surgery, as determined by [ABX Notes Phenotype](#) (value code 2)
- Non-cardiac, Transcatheter/Endovascular, EP/Cath groups and Other Cardiac cases as determined by the [Procedure Type: Cardiac](#) phenotype
- [Procedure Type: Lung Transplant](#)

ABX-03-C: Antibiotic Redosing, Open Cardiac Procedures

- **Attribution:**

- All anesthesia providers signed in at the time of each re-dose (if not given: 255 minutes after initial cephalosporin dose, and/or if not given: 255 minutes after the first re-dose)

- **Notes:**


- Ceftriaxone & cefotetan are excluded due to extended half-lives as compared to more commonly used cephalosporins. Redosing not recommended.
- Cefoxitin excluded: non-standard antibiotic for cardiac cases with short half-life.

- **Recent Updates:**

- **Infusions now considered (start time determines re-dose window). If still running at time of re-dose = pass.**
- **If re-dosed within 255 minutes before surgery end = pass, if not = exclude.**


Unblinded data removed from slides published to website.

Antibiotic Redosing: Breakdown of Flagged Cases



Unblinded data removed from slides published to website.

Number of Redoses per Case ABX-03-C Passed Cases Only



Unblinded data removed from slides published to website.

ABX-03-C Discussion

- Some cases are re-dosed just prior to surgical incision in an effort to achieve optimal blood concentration levels at time of incision. These cases flag as 'Re-dosed too early' currently. Is this appropriate?

2:49:00 PM CEFUROXIME 1.5 GM

3:10:00 PM Anesthesia Start

3:50:00 PM CEFUROXIME 1.5 GM **Flagged: Re-dose too early**

4:50:00 PM Procedure Start

7:51:00 PM CEFUROXIME 1.5 GM

8:48:00 PM Procedure End

9:02:00 PM Anesthesia End

- If there are multiple doses prior to incision (procedure start), should we only consider the most recent dose and ignore earlier doses?

ABX-04 Antibiotic Selection, Open Cardiac Procedures

- **Description:**

- Percentage of adult patients undergoing open cardiac surgery with the recommended antibiotic agents administered for surgical site infection prophylaxis.

- **Timing:**

- 120 minutes prior to Anesthesia Start through Anesthesia End

- **Attribution:**

- All anesthesia providers signed in at the time of Anesthesia Start Time

ABX-04 Antibiotic Selection Considerations

- **Inclusions:**

- Adult patients undergoing open cardiac surgical procedures

- **Exclusions:**

- Age < 18 years
- ASA 6 including Organ Procurement
- Patients already on scheduled antibiotics or had a documented infection prior to surgery, as determined by “Patient on Scheduled Antibiotics/Documented Infection” (value: 2) of the [ABX Notes Phenotype](#)
- Non-cardiac, Transcatheter/Endovascular, EP/Cath groups and Other Cardiac cases as determined by the [Procedure Type: Cardiac](#) phenotype
- Lung Transplant cases as determined by the [Procedure Type: Lung Transplant](#) phenotype

ABX-04 Antibiotic Selection Considerations

- **Acceptable antibiotic combinations for Open Cardiac Procedures:**
 - Vancomycin + Cephalosporin
 - Vancomycin + Aminoglycoside
 - Cephalosporin Only


ABX-04 Antibiotic Selection Considerations

Cases will be assigned one of the following result reasons:


- Passed - Vancomycin + Cephalosporin
- Passed - Vancomycin + Aminoglycoside
- Passed - Cephalosporin Only
- Flagged - Non-standard antibiotic selection
- Flagged - Prophylactic antibiotic not administered (Not documented in MAR)
- Flagged - Antibiotic not ordered/indicated per surgeon
- Flagged - Not administered for medical reasons
- Excluded - Scheduled antibiotics/documentated infection

Unblinded data removed from slides published to website.

Antibiotic Selection: Breakdown of Flagged Cases



Antimicrobial Agent Combinations ABX-04: Passed Cases



ABX-04-C Discussion

- Should vancomycin + 'any antibiotic with gram negative' coverage = pass?
 - Ex. Currently, vanco + Zosyn or vanco + aztreonam are flagged

ABX-05 Composite Antibiotic Compliance for Open Cardiac

- **Description:**

- Percentage of adult patients undergoing open cardiac surgery with appropriate antibiotic selection, timing, and re-dosing administered for surgical site infection prophylaxis.

- **Timing:**

- 120 minutes prior to Anesthesia Start Time through Anesthesia End Time

- **Attribution: Departmental Only**

- Case level attribution, viewable on the dashboard at the case level, not provided to individual clinicians

- **Success:**

- Case must pass all antibiotic prophylaxis measures for which the case is not excluded for open cardiac procedure measures (must be included in at least one ABX measure to be a candidate for the composite measure)
 - ABX-02-C / ABX-03-C / ABX-04-C

ABX-05 Composite Antibiotic Compliance Considerations

- **Inclusions:**

- Adult patients undergoing open cardiac surgical procedures

- **Exclusions:**

- Age < 18 years
- ASA 6 including Organ Procurement
- Patients already on scheduled antibiotics or had a documented infection prior to surgery, as determined by “Patient on Scheduled Antibiotics/Documented Infection” (value: 2) of the [ABX Notes Phenotype](#)
- Non-cardiac, Transcatheter/Endovascular, EP/Cath groups and Other Cardiac cases as determined by the [Procedure Type: Cardiac](#) phenotype
- Lung Transplant cases as determined by the [Procedure Type: Lung Transplant Phenotype](#)

ABX-05-C - Other Measure Build Details


Cases will be assigned one of the following result reasons:

- Passed - Antibiotic Prophylaxis Standards Met
- Flagged - Timing, Re-dosing, & Selection Not Met (ABX-02-C, ABX-03-C, & ABX-04-C flagged)
- Flagged - Timing & Selection Not Met (ABX-02-C & ABX-04-C flagged)
- Flagged - Re-dosing & Selection Not Met (ABX-03-C & ABX-04-C flagged)
- Flagged - Timing & Re-dosing Not Met (ABX-02-C & ABX-03-C flagged)
- Flagged - Antibiotic not administered on time (ABX-02-C flagged)
- Flagged - Antibiotic not appropriately re-dosed (ABX-03-C flagged)
- Flagged - Non-standard antibiotics selection (ABX-04-C flagged)
- Excluded - Scheduled antibiotics/documentated infection


*Case must be included and passed for at least one of the antibiotic measures to be included for ABX-05. If any measure is flagged, ABX-05 will also be flagged.

Unblinded data removed from slides published to website.

Antibiotic Composite: Breakdown of Flagged Cases



Antibiotic Composite: Breakdown of Passed Cases



Unblinded data removed from slides published to website.

Acute Kidney Injury - Open Cardiac Surgery

AKI-02-C: Acute Kidney Injury in patients undergoing Open Cardiac Surgery

Description: Percentage of patients undergoing an open cardiac procedure with a baseline creatinine increase of more than 1.5 times within 7 postoperative days or the baseline creatinine level increases by ≥ 0.3 mg/dL within 48 hours postoperatively.

Inclusion: Adult patients undergoing open cardiac surgical procedures (determined by Procedure Type: Cardiac value code: 1)

Success:

1. The creatinine level does not go above 1.5x the baseline creatinine within 7 days post-op
2. The creatinine level does not increase by ≥ 0.3 mg/dL obtained within 48 hours after anesthesia end.

Reported as an inverse measure.

AKI-02-C: Acute Kidney Injury in patients undergoing Open Cardiac Surgery

Exclusions:

- ASA 6 (including CPT:01990)
- Cases where a baseline creatinine is not available within 60 days preoperatively
- Cases where a creatinine lab is not available within 7 postoperative days.
- Patients with more than one case in a 7-day period. The first case will be excluded if a postop creatinine is not documented for that first case. For example, a patient that has surgery twice in a 7-day period, the first surgery is excluded if a creatinine is not drawn in between cases
- Patients with pre-existing renal (stage 4 or 5) failure based upon BSA-Indexed EGFR $< 30 \text{ mL/min/1.73m}^2$ determined by Preop EGFR (most recent) or MPOG Complication - Acute Kidney Injury (value code -2.
- Open cardiac procedures performed in conjunction with procedures affecting the kidney, bladder, or ureter (see spec for specific anesthesia and surgical CPT codes).
- Liver Transplants

Unblinded data removed from slides published to website.

Unblinded data removed from slides published to website.

Acute Kidney Injury in Cardiac Surgery Toolkit



About Sites Research Quality Tools Downloads News/Events

Quality Toolkits

MPOG QI measure toolkits are designed to improve care and patient outcomes through the adoption of best practices. MPOG QI toolkits contain a collection of educational resources, articles, and reference guides. Materials within are intended for widespread use across the collaborative to facilitate the sharing of best practices.



Acute Kidney Injury (AKI)

[Click Here](#)



Acute Respiratory Complications

[Click Here](#)



Patient Blood Management

[Click Here](#)

Acute Kidney Injury Prevention Toolkit for Cardiac Surgery has been updated!

[2023 STS/SCA/AmSECT Clinical Practice Guidelines for the Prevention of Adult Cardiac Surgery-Associated AKI](#) now included:

[MPOG CS-AKI Toolkit](#)



Summary/Next Steps

- New measure development - plan to share prelim data at next meeting:
 - Transfusion ratios (1:1:1)
 - Hypotension (anesthesia start - procedure start)
- **Next Meeting:**
 - February 2025
 - June 2025
 - November 2025
- Thank you for using the [forum](#) for discussion between meetings

Thank you!

Allison Janda, MD
MPOG Cardiac Anesthesia
Subcommittee Chair
ajanda@med.umich.edu